Marinus (MRNS) Gets a Buy Rating from Ladenburg Thalmann & Co.

By Austin Angelo

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus (MRNSResearch Report) today and set a price target of $5.00. The company’s shares closed last Monday at $1.09, close to its 52-week low of $0.77.

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -16.5% and a 26.7% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $5.67 average price target, implying a 401.8% upside from current levels. In a report issued on November 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.

See today’s analyst top recommended stocks >>

Based on Marinus’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.81 million. In comparison, last year the company had a GAAP net loss of $11.11 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.